The effect of inhaled aromatherapy on cognitive function in patients with cognitive impairment: A systematic review and meta-analysis.

IF 4.1 2区医学 Q1 PSYCHIATRY

General hospital psychiatry Pub Date : 2025-01-09 DOI:10.1016/j.genhosppsych.2025.01.002

Guiting Su, Fang Liu, Xiaoqiu Yang, Ziqiong Chen, Yahong Kang, Shan Gao

{"title":"The effect of inhaled aromatherapy on cognitive function in patients with cognitive impairment: A systematic review and meta-analysis.","authors":"Guiting Su, Fang Liu, Xiaoqiu Yang, Ziqiong Chen, Yahong Kang, Shan Gao","doi":"10.1016/j.genhosppsych.2025.01.002","DOIUrl":null,"url":null,"abstract":"Background and purpose: Cognitive function is the basis of human thinking and behavior. Cognitive impairment has a serious impact on each individual and imposes a financial burden to families and healthcare systems. Inhalation aromatherapy has advantages, due to its safety, convenience, lack of toxicity, and wide use in the treatment of cognitive impairment. This systematic review was conducted to provide evidence for the use of inhaled aromatherapy in patients with cognitive impairment.Methods: We searched nine databases for pertinent Chinese and English studies published through November 2024 studies using inhaled aromatherapy in patients with cognitive impairment. Literature screening and data extraction were performed independently by two researchers and evaluated using the Cochrane Collaboration's quality criteria and were then cross-checked. A meta-analysis was carried out using Cochrane's Review Manager (RevMan, version 5.4), and we followed the PRISMA guidelines.Results: We included fourteen studies involving 888 patients with cognitive impairment in our study. Meta-analyses indicated that inhaled aromatherapy increased Mini-mental State Examination (MMSE, mean difference MD = 3.89 95 % CI [3.19, 4.58], P < 0.00001) and Montreal Cognitive Assessment Scale (MoCA, MD = 4.11, 95 % CI [3.54, 4.68], P < 0.00001) scores and decreased Homocysteine levels (Hcy, MD = -2.27 95 % CI [-2.80, -1.74], P < 0.00001) in patients with cognitive impairment compared with controls.Conclusion: Inhaled aromatherapy could improve global cognition and lower Hcy in patients with cognitive impairment.","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"93 ","pages":"20-31"},"PeriodicalIF":4.1000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"General hospital psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.genhosppsych.2025.01.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: Cognitive function is the basis of human thinking and behavior. Cognitive impairment has a serious impact on each individual and imposes a financial burden to families and healthcare systems. Inhalation aromatherapy has advantages, due to its safety, convenience, lack of toxicity, and wide use in the treatment of cognitive impairment. This systematic review was conducted to provide evidence for the use of inhaled aromatherapy in patients with cognitive impairment.

Methods: We searched nine databases for pertinent Chinese and English studies published through November 2024 studies using inhaled aromatherapy in patients with cognitive impairment. Literature screening and data extraction were performed independently by two researchers and evaluated using the Cochrane Collaboration's quality criteria and were then cross-checked. A meta-analysis was carried out using Cochrane's Review Manager (RevMan, version 5.4), and we followed the PRISMA guidelines.

Results: We included fourteen studies involving 888 patients with cognitive impairment in our study. Meta-analyses indicated that inhaled aromatherapy increased Mini-mental State Examination (MMSE, mean difference MD = 3.89 95 % CI [3.19, 4.58], P < 0.00001) and Montreal Cognitive Assessment Scale (MoCA, MD = 4.11, 95 % CI [3.54, 4.68], P < 0.00001) scores and decreased Homocysteine levels (Hcy, MD = -2.27 95 % CI [-2.80, -1.74], P < 0.00001) in patients with cognitive impairment compared with controls.

Conclusion: Inhaled aromatherapy could improve global cognition and lower Hcy in patients with cognitive impairment.

查看原文本刊更多论文

背景和目的：认知功能是人类思维和行为的基础。认知障碍对每个人都有严重影响，并给家庭和医疗系统带来经济负担。吸入芳香疗法具有安全、方便、无毒性等优点，被广泛用于认知障碍的治疗。本系统综述旨在为认知障碍患者使用吸入式芳香疗法提供证据：我们在九个数据库中检索了截至 2024 年 11 月发表的使用吸入式芳香疗法治疗认知障碍患者的相关中英文研究。文献筛选和数据提取由两名研究人员独立完成，采用 Cochrane 协作组织的质量标准进行评估，然后进行交叉核对。我们使用 Cochrane 的综述管理器（RevMan，5.4 版）进行了荟萃分析，并遵循了 PRISMA 指南：我们共纳入了 14 项研究，涉及 888 名认知障碍患者。元分析表明，吸入芳香疗法可提高迷你精神状态检查（MMSE，平均差 MD = 3.89 95 % CI [3.19, 4.58]，P 结论：吸入芳香疗法可改善认知障碍患者的认知能力：吸入芳香疗法可改善认知障碍患者的整体认知能力并降低 Hcy。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

General hospital psychiatry 医学-精神病学

CiteScore

9.60

自引率

2.90%

发文量

125

审稿时长

20 days

期刊介绍： General Hospital Psychiatry explores the many linkages among psychiatry, medicine, and primary care. In emphasizing a biopsychosocial approach to illness and health, the journal provides a forum for professionals with clinical, academic, and research interests in psychiatry''s role in the mainstream of medicine.